Back to top

Summit Therapeutics price target lowered to $15 from $17 at Jefferies

Jefferies lowered the firm’s price target on Summit Therapeutics (SMMT) to $15 from $17 and keeps a Hold rating on the shares, contending that the ...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Summit Therapeutics PLC (SMMT)